Spots Global Cancer Trial Database for recurrent adrenal gland pheochromocytoma

Every month we try and update this database with for recurrent adrenal gland pheochromocytoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor	NCT02831179	Functional Panc... Malignant Somat... Merkel Cell Car... Metastatic Adre... Metastatic Carc... Multiple Endocr... Multiple Endocr... Multiple Endocr... Neuroendocrine ... Non-Functional ... Pancreatic Gluc... Pancreatic Insu... Recurrent Adren... Recurrent Adren... Recurrent Merke... Somatostatin-Pr... Stage III Adren... Stage III Thyro... Stage IIIA Merk... Stage IIIB Merk... Stage IV Adrena... Stage IV Merkel... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thymic Carcinoi... VIP-Producing N... Well Differenti... Zollinger Ellis...	Capecitabine Temozolomide Veliparib Pharmacological... Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04284774	Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ...	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib	12 Months - 21 Years	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma	NCT01340794	Extra-Adrenal P... Metastatic Adre... Paraganglioma Recurrent Adren...	Laboratory Biom... Pazopanib Hydro...	18 Years -	National Cancer Institute (NCI)
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor	NCT02831179	Functional Panc... Malignant Somat... Merkel Cell Car... Metastatic Adre... Metastatic Carc... Multiple Endocr... Multiple Endocr... Multiple Endocr... Neuroendocrine ... Non-Functional ... Pancreatic Gluc... Pancreatic Insu... Recurrent Adren... Recurrent Adren... Recurrent Merke... Somatostatin-Pr... Stage III Adren... Stage III Thyro... Stage IIIA Merk... Stage IIIB Merk... Stage IV Adrena... Stage IV Merkel... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thymic Carcinoi... VIP-Producing N... Well Differenti... Zollinger Ellis...	Capecitabine Temozolomide Veliparib Pharmacological... Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: